2023 World Conference on Lung Cancer (Posters)-EP17.04. Clinical Outcomes and Lack of Health Equity in Minority Patients with Unresectable Non-small Cell Lung Cancer (NSCLC) Treated with Durvalumab

EP17.04. Clinical Outcomes and Lack of Health Equity in Minority Patients with Unresectable Non-small Cell Lung Cancer (NSCLC) Treated with Durvalumab - PDF(Abstract)

Back to course

Pdf Summary

This presentation focuses on the clinical outcomes and lack of health equity in minority patients with unresectable non-small cell lung cancer (NSCLC) who were treated with durvalumab. The study aimed to compare the outcomes of non-Hispanic Whites (NHW) with minorities (Blacks and Hispanics) who had locally advanced or inoperable NSCLC. <br /><br />The researchers conducted a retrospective analysis of patients who received durvalumab at Memorial Cancer Institute between January 2018 and March 2022. Data collected included patient demographics, treatment response, progression-free survival (PFS), and overall survival (OS). The patients were divided into NHW and minority cohorts.<br /><br />A total of 79 patients (42 NHW and 37 minorities) received durvalumab. The NHW group had a better PFS with a 24-month PFS rate of 44.6% compared to 38.4% in the minority group. The 24-month OS rate was also higher in the NHW group (83.4% vs. 67.8% in minorities) but the differences were not statistically significant.<br /><br />Further subgroup analysis within the minority cohort showed that Hispanics had inferior PFS and OS rates compared to Blacks. The limitations of the study include a small sample size and short follow-up period.<br /><br />The findings of the study suggest that minority patients with unresectable NSCLC may have inferior clinical outcomes compared to NHW patients. The lack of diversity in most published clinical trials on NSCLC highlights the importance of more research in this area.

Asset Subtitle

Luis Raez

Meta Tag

Speaker Luis Raez

Topic Global Health, Health Services & Health Economics: Real World Data

Keywords

clinical outcomes

health equity

minority patients

NSCLC

durvalumab

non-Hispanic Whites

treatment response

progression-free survival

overall survival

diversity